Skip to main
KOD

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences is a promising company with a bright future ahead. Their innovative technology platform, the ABC platform, has shown great potential in the development of retinal medicines. Their investigational medicines, tarcocimab tedromer, KSI-501, and KSI-101, have shown positive results in clinical trials, giving confidence in their potential for approval and commercial success. With data expected in the coming quarters and a strong financial position, Kodiak Sciences is a company to watch in the biopharmaceutical sector.

Bears say

Kodiak Sciences is currently in the pre-commercial stage with three late-stage clinical programs in development, however, they face numerous risks including binary risks surrounding future datasets, potential regulatory delays, and the requirement to build a global infrastructure for sales and marketing which could increase cash burn and result in dilution for shareholders. In addition, the success of Kodiak's proprietary ABC platform relies on their ability to manufacture biologics, and their issued patents will expire relatively soon, leaving the company vulnerable to competition.

KOD has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 7 analysts, KOD has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.